Description: PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control. In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified. PCL, Inc. is headquartered in Seoul, South Korea.
Home Page: www.pclchip.com
Star valley, 99
Seoul,
08510
South Korea
Phone:
82 2 2144 3901
Officers
| Name | Title |
|---|---|
| Ms. So-Youn Kim | Chief Exec. Officer |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 5.3745 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |